Fibrocell Science Inc

Fibrocell Science — Investor Presentation (June 2017)

18 slides from Fibrocell Science's investor presentation, Jun 21, 2017

  1. Slide 1: Corporate Presentation June 21, 2017

    Corporate Presentation June 21, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Fibrocell at a Glance

    Proprietary autologous fibroblast cell capabilities + Ex vivo genetic modification of patients’ own fibroblast cells FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Localized Scleroderma Arthritis and related conditions 3 Fibrocell at a Glance Personalized medical breakthroughs for

  4. Slide 4: Our Autologous Fibroblast Gene Therapy Platform

    Autologous fibroblasts harvested from patients • Readily sourced, as fibroblasts are the most common cell type in skin and connective tissue • Reduced rejection and immunogenicity concerns because the donor is the patient • Established manufacturing process and regulatory pathway for autologous fibr

  5. Slide 5: Personalized Biologics Approach

    Personalized Biologics Approach 5

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologic Condition Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Localized Scleroderma Research Program Arthritis Human data expected 3Q17 IND filing expected 4Q17

  7. Slide 7: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 7 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene • Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1

  8. Slide 8: About RDEB

    About RDEB 8 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate – 76% of RDEB suffers do not live past their 30’s2 • Current

  9. Slide 9: Functional COL7 Expression Confirmation

    Functional COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruc

  10. Slide 10: Detection of COL7 Expression by Immunofluorescence

    10 Detection of COL7 Expression by Immunofluorescence (Magnification 20x) • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression of COL7 in RDEB-positive fib

  11. Slide 11: FCX-007 Phase 1/2 Clinical Trial Design

    Phase 1: 1st patient dosed Feb. 2017 • Continue follow-up at 4- and 12-weeks • Respond to FDA with benefit and safety data in adults and toxicology study Phase 1: Dose additional adult patients Phase 2 Pediatrics FCX-007 Phase 1/2 Clinical Trial Design 11 Title A Phase 1/2 Trial of FCX-007 (Genetica

  12. Slide 12: FCX-013 Development Progressing

    FCX-013 Development Progressing 12 • Product profile  Autologous fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down excess collagen  Target protein known to breakdown collagens  Incorporates Intrexon’s Rheo

  13. Slide 13: FCX-013 employs Intrexon's RheoSwitch Therapeutic System

    • FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®)  The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression • Enhances the safety profile of FCX-013 by providing control over t

  14. Slide 14: Localized Scleroderma

    Localized Scleroderma 14 Disease Epidemiology • Excess production of collagen characterized by skin fibrosis and scars • Focus on moderate to severe subtypes, including linear • Thickening may extend to underlying tissue and muscle in children which may impair growth in affected limbs or forehead •

  15. Slide 15: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 15 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  16. Slide 16: Research Program for Arthritis

    Research Program for Arthritis 16 • Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localiz

  17. Slide 17: Milestones and Financials

    Milestones and Financials 17 Milestones Anticipated Timing FCX-007 1st Adult Patient Dosed February 2017 FCX-007 DSMB Recommendation May 2017 FCX-007 Phase 1/2 Trial First human clinical data 3Q17 FCX-013 IND Filing 4Q17 Financials • Cash = $18.2 million at March 31, 2017 • Closed public offering wi

  18. Slide 18: References

    References 1 Fritsch A., et. al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanism of disease and response to fibroblast therapy. J Clin Invest.2008; 118:1669–1679. 2 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the

Fibrocell Science — Investor Presentation (June 2017) on 6ix